raludotatug deruxtecan/MK-5909 and ifinatamab deruxtecan/MK-2400 from Japan’s Daiichi Sankyo in October last year for a total potential consideration of up to $22 billion. While raludotatug ...

MSD and Daiichi Sankyo have revealed some of the clinical data that prompted them to start pivotal testing of ifinatamab deruxtecan (I-DXd) in patients with previously treated, extensive-stage ...

Ifinatamab deruxtecan (I-DXd), meanwhile, is in mid-stage testing in previously treated extensive-stage small cell lung cancer (SCLC), with phase 1/2 results showing signs of activity, while ...

raludotatug deruxtecan/MK-5909 and ifinatamab deruxtecan/MK-2400. While Merck/Daiichi’s patritumab deruxtecan is under review ...

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

Clinical research conducted with participation from Florida Cancer Specialists & Research Institute, LLC (FCS) continues to ...

Some of the key B7-H3 inhibitors in the pipeline include Ifinatamab deruxtecan (I-DXd), Vobramitamab duocarmazine, Enoblituzumab, GSK5764227/HS-20093, and others. In February 2024, Mabwell ...

Medscape Medical News, September 12, 2024 WCLC 2024 Ifinatamab Deruxtecan Effective in ES-SCLC Patients with pretreated extensive small cell lung cancer could benefit from the antibody-drug ...

Medscape Medical News, September 11, 2024 WCLC 2024 Ifinatamab Deruxtecan Effective in ES-SCLC Patients with pretreated extensive small cell lung cancer could benefit from the antibody-drug ...

Some are leveraging Merck's partnership with Daiichi Sankyo to develop antibody drug conjugates ("ADCs"), a pioneering new type of dual action therapy (two candidates to date - ifinatamab ...